The company’s board of directors has retained Goldman Sachs and Co. as a financial advisor to undertake an evaluation of strategic alternatives, including a corporate sale, merger, or business combination.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRAY:
- ViewRay Falls on Preliminary Q1 Numbers; Outlook Disappoints
- ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value
- ViewRay sees no material impact to operations from SVB’s closure, receivership
- ViewRay announces Czech Ministry of Health approval of MRIdian purchase
- ViewRay sees FY23 sees total revenue increase of 25%-40%
